Discussion on when differentiated thyroid cancer is determined to be iodine-refractory, and how patients should be followed in this setting. Health care specialists share insight on the work-up of ...

Considerations for the role of patient advocacy groups and patient-to-patient education in the differentiated thyroid cancer journey. Lori Wirth, MD: I think that one of the reasons that a ...

Please provide your email address to receive an email when new articles are posted on . In an analysis of data from more than 600 survivors of differentiated thyroid cancer at a clinic in Germany, ...

A new study has shown that overall and cause-specific mortality rates in individuals in the U.S. with low-risk differentiated thyroid cancer (DTC) are low. The study is published in the peer-reviewed ...

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma Using nine US SEER cancer registries (1975-2017), we ...

A Sarasota Memorial specialist helped create new guidelines for treating differentiated thyroid cancer. The "2025 American Thyroid Association Management Guidelines" are the first update since 2015.

Graphical Abstract. Relative survival with and without radioiodine therapy (RAI) in intermediate risk papillary thyroid cancer (PTC) and low risk, minimally invasive follicular thyroid cancer (FTC). A ...

Receiving a diagnosis of thyroid cancer can be upsetting and confusing, especially if a doctor suggests that a patient wait to see how the cancer progresses before pursuing any specific treatment.

Eisai announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 ...

CHICAGO — Patients who are new users of glucagon-like peptide-1 (GLP-1) receptor agonists have a low absolute risk of thyroid cancer, according to a new study presented at the American Thyroid ...